Read

Over the past five years, Sally struggled with depression, and despite trying various treatments, none seemed to benefit her. Recently, she visited a new psychiatrist who conducted a saliva swab for pharmacogenetic testing during her initial consultation. By combining Sally’s medication history and the pharmacogenetic test results, the psychiatrist discovered that several previously prescribed medications

Hemgenix became the most expensive drug in the history of FDA-approvals back in November of 2022 after the manufacturer, CSL Behring, hung a $3.5 million dollar price tag on it. This was a first-of-its-kind therapy approved for the treatment of hemophilia, more specifically hemophilia B. Hemgenix is one of the newest agents utilizing gene therapy

This might come as a surprise to some individuals as they dive into the listed ingredients of the newest FDA-approved anti-depressant to hit the market, Auvelity. Let’s take a look at this new product and how a cough medicine found its way into this new treatment.  Auvelity is a combination product that contains dextromethorphan (yes,

The industry report you’ve been waiting for. Today biosimilars seem to be the topic of conversation everywhere. Why? Humira. The launch of Humira biosimilars will be a test for industry stakeholders, as their entrance will reveal whether blockbuster drugs—that offer significant rebates—can be replaced to reduce the cost burden on patients and payers in the United States. Download our

As industry experts, it’s the number one topic we’re being asked to comment on. While biosimilars have existed for many years, the topic has been gaining some serious new attention as AbbVie’s Humira—the number one selling drug in the U.S.—no longer has exclusivity in the market.   Will biosimilar competitors increase competition, lower drug costs and